A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Current Oncology · 2023
DOI: 10.3390/curroncol30100669 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology, 2023. Verfasst von Zakaria Alameddine und 9 weiteren Autor:innen. Beteiligte Einrichtung: Staten Island University Hospital, Staten Island, NY 10305, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to better characterize the progression-free survival (PFS) and overall survival (OS) in metastatic CRPC patients treated with PARPis. A systemic review search was conducted using National Clinical Trial (NCT), PubMed, Embase, Scopus, and Central Cochrane Registry. The improvement in overall survival was statistically significant, favoring PARPis (hazard ratio (HR) 0.855; 95% confidence interval (CI) 0.752–0.974; p = 0.018). The improvement in progression-free survival was also statistically significant, with results favoring PARPis (HR 0.626; 95%CI 0.566–0.692; p = 0.000). In a subgroup analysis, similar results were observed where the efficacy of PARPis was evaluated in a subgroup of patients without homologous recombination repair (HRR) gene mutation, which showed improvement in PFS favoring PARPis (HR 0.747; 95%CI 0.0.637–0.877; p = 0.000). Our meta-analysis of seven RCTs showed that PARPis significantly increased PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Staten Island University Hospital, Staten Island, NY 10305, USA.
- University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA.
ORCID-Profile: Zakaria Alameddine, Muhammad Rafay Khan Niazi
Zitieren
APA
Alameddine, Z., Niazi, M. R. K., Rajavel, A., Behgal, J., Keesari, P. R., Araji, G., Mustafa, A., Wei, C., Jahangir, A., & Terjanian, T. O. (2023). A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Current Oncology. https://doi.org/10.3390/curroncol30100669
Vancouver
Alameddine Z, Niazi MRK, Rajavel A, Behgal J, Keesari PR, Araji G, et al. A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Current Oncology. 2023. doi:10.3390/curroncol30100669
BibTeX
@article{Alameddine2023,
author = {Alameddine, Zakaria and Niazi, Muhammad Rafay Khan and Rajavel, Anisha and Behgal, Jai and Keesari, Praneeth Reddy and Araji, Ghada and Mustafa, Ahmad and Wei, Chapman and Jahangir, Abdullah and Terjanian, Terenig O},
title = {A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30100669}
}
EUVIMED